Knight Therapeutics Company Profile (TSE:GUD)

About Knight Therapeutics

Knight Therapeutics logoKnight Therapeutics Inc. is a specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. The Company finances other life sciences companies in Canada and internationally with the goal of earning interest income and securing product distribution rights for Canada and select international markets. It invests in life sciences venture capital funds whereby the Company earns a return similar to any other limited partner in the fund and receives preferential access to healthcare products from around the world for Canada and select international markets. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO and VEWS Vascular Early Warning System.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: TSE
  • Symbol: GUD
  • CUSIP:
Key Metrics:
  • Previous Close: $8.52
  • 50 Day Moving Average: $8.37
  • 200 Day Moving Average: $8.05
  • 52-Week Range: C$5.89 - C$8.75
  • Trailing P/E Ratio: 52.98
  • P/E Growth: 2813.33
  • Market Cap: $1.13B
  • Outstanding Shares: 132,701,000
Additional Links:

Analyst Ratings

Consensus Ratings for Knight Therapeutics (TSE:GUD) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: C$9.25

Analysts' Ratings History for Knight Therapeutics (TSE:GUD)
Show:
DateFirmActionRatingPrice TargetDetails
7/18/2016ScotiabankReiterated RatingOutperformC$9.50View Rating Details
6/7/2016TD SecuritiesLower Price TargetBuyC$10.00 -> C$9.00View Rating Details
5/31/2016CIBCReiterated RatingOutperformC$9.50View Rating Details
3/10/2016Paradigm CapitalSet Price TargetBuyC$9.00View Rating Details
3/2/2016Dundee SecuritiesReiterated RatingNeutralView Rating Details
5/14/2015LaurentianLower Price TargetHoldC$9.50 -> C$8.50View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Knight Therapeutics (TSE:GUD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/15/2014($0.01)$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Knight Therapeutics (TSE:GUD)
Current Year EPS Consensus Estimate: $0.10 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.06$0.06$0.06
Q2 20161$0.06$0.06$0.06
Q3 20161$0.04$0.04$0.04
Q4 20161$0.04$0.04$0.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Knight Therapeutics (TSE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Knight Therapeutics (TSE:GUD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2015Robert Nathaniel LandeDirectorSell57,000C$8.85C$504,267.60
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Knight Therapeutics (TSE:GUD)
DateHeadline
capitalcube.com logoKnight Therapeutics, Inc. :GUD-CA: Earnings Analysis: Q2, 2016 By the Numbers : August 19, 2016 (TSE:GUD)
www.capitalcube.com - August 19 at 5:20 PM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : GUD-CA : August 18, 2016 (TSE:GUD)
www.capitalcube.com - August 18 at 5:22 PM
marketwired.com logoA Knight is Reborn - Marketwired (press release) (TSE:GUD)
www.marketwired.com - August 17 at 5:35 PM
finance.yahoo.com logoA Knight is Reborn (TSE:GUD)
finance.yahoo.com - August 17 at 8:22 AM
marketwired.com logoKnight Therapeutics Inc.: In the Beginning of a Genesys Partnership - Marketwired (press release) (TSE:GUD)
www.marketwired.com - August 16 at 8:43 AM
finance.yahoo.com logoKnight Therapeutics Inc.: In the Beginning of a Genesys Partnership (TSE:GUD)
finance.yahoo.com - August 16 at 8:43 AM
finance.yahoo.com logoKnight Lends a Second Hand to Bloom Burton Debt Fund (TSE:GUD)
finance.yahoo.com - August 12 at 8:28 AM
4-traders.com logoKnight Therapeutics : Reports Second Quarter 2016 Results (TSE:GUD)
www.4-traders.com - August 11 at 5:34 PM
finance.yahoo.com logoKnight Reports Second Quarter 2016 Results (TSE:GUD)
finance.yahoo.com - August 11 at 8:20 AM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : August 4, 2016 (TSE:GUD)
www.capitalcube.com - August 4 at 5:40 PM
marketwired.com logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX(TM) - Marketwired (press release) (TSE:GUD)
www.marketwired.com - August 4 at 8:18 AM
finance.yahoo.com logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX(TM) (TSE:GUD)
finance.yahoo.com - August 2 at 5:37 PM
stockhouse.com logoKNIGHT THERAPEUTICS INC T.GUD (TSE:GUD)
www.stockhouse.com - July 25 at 9:57 AM
finance.yahoo.com logo3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and Distribution Agreements With Knight ... - Yahoo Finance (TSE:GUD)
finance.yahoo.com - July 22 at 8:17 AM
marketwired.com logo3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and Distribution Agreements With Knight ... - Marketwired (press release) (TSE:GUD)
www.marketwired.com - July 21 at 5:32 PM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : July 18, 2016 (TSE:GUD)
www.capitalcube.com - July 18 at 8:28 AM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : July 7, 2016 (TSE:GUD)
www.capitalcube.com - July 7 at 8:26 AM
finance.yahoo.com logoKnight and Ember Expand Distribution Partnership (TSE:GUD)
finance.yahoo.com - July 6 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : June 20, 2016 (TSE:GUD)
www.capitalcube.com - June 20 at 8:43 AM
finance.yahoo.com logoKnight Therapeutics Inc. Announces Election of Directors (TSE:GUD)
finance.yahoo.com - June 16 at 6:00 PM
theglobeandmail.com logoThis company is cashed up for growth while limiting downside risk (TSE:GUD)
www.theglobeandmail.com - June 3 at 5:38 PM
marketwired.com logoKnight Therapeutics Completes Previously Announced Bought Deal of Common Shares, Including Exercise of Over-Allotment Option, for $230 million (TSE:GUD)
www.marketwired.com - June 2 at 5:34 PM
finance.yahoo.com logoKnight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City (TSE:GUD)
finance.yahoo.com - May 31 at 8:00 AM
marketwired.com logo3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into ... - Marketwired (press release) (TSE:GUD)
www.marketwired.com - May 26 at 2:14 PM
4-traders.com logoKnight Therapeutics : Breaks Glass on Medimetriks Partnership (TSE:GUD)
www.4-traders.com - February 26 at 2:20 PM
finance.yahoo.com logoKnight Breaks Glass on Medimetriks Partnership (TSE:GUD)
finance.yahoo.com - February 17 at 8:54 AM
finance.yahoo.com logoBraeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE® (TSE:GUD)
finance.yahoo.com - February 1 at 8:00 AM
finance.yahoo.com logoBraeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE(R) (TSE:GUD)
finance.yahoo.com - February 1 at 8:00 AM
finance.yahoo.com logoINTEGA Skin Looks GUD to Knight (TSE:GUD)
finance.yahoo.com - January 25 at 11:00 AM

Social

Knight Therapeutics (TSE:GUD) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff